Clinical Trials Browser

Phase 2 × darolutamide × Breast × Clear all

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

Phase 2 Not yet recruiting

BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

NCT03383679 2022-11-21

START

Phase 2 Completed

Breast Cancer Female